Arife Sabancı1, Basak Karasu2, Halil Ibrahim Sabancı3, İrfan Kuku4, Omer Alperen Kırmızıgul5. 1. Department of Periodontology, Faculty of Dentistry, Inonu University, 44280, Malatya, Turkey. dtcicekarife@hotmail.com. 2. Department of Periodontology, Karatekin University, Çankırı, Turkey. 3. Department of Internal Medicine, Inonu University, Malatya, Turkey. 4. Department of Internal Medicine - Hematology, Inonu University, Malatya, Turkey. 5. Department of Periodontology, Inonu University, Malatya, Turkey.
Abstract
OBJECTIVES: Oral mucositis (OM) is a frequent complication of cancer treatments. Oral mucositis and periodontal disease have a common inflammatory pattern. The purpose of this study was to evaluate the OM and its association with periodontal status in patients with hematologic malignancies who undergo high-dose chemotherapy. MATERIALS AND METHODS: Fifty-five patients who received high-dose chemotherapy were included in the study. Full-mouth periodontal clinical measurements including plaque index (PI), gingival index (GI), clinical attachment level (CAL), and probing depth (PD) values were recorded before the condition chemotherapy regime. OM monitoring was initiated 1 day after the chemotherapy and maintained for 20 days. RESULTS: Twenty-two of patients (40%) were observed oral mucositis after high-dose chemotherapy. Patients with mucositis had significantly higher GI scores than those who did not have mucositis (p < 0.05). There was a significantly moderate positive correlation between the grade of mucositis and GI scores (p < 0.05). In patients with periodontitis, the incidence of grade 1-2 mucositis was significantly higher than in the healthy group (p < 0.05). In individuals with periodontitis and gingivitis, the healing duration of mucositis was significantly longer than the healthy group (p < 0.05). CONCLUSIONS: The results of this study showed that the severity grades of oral mucositis may increase in patients with gingival inflammation. The results also suggest that periodontal diseases may have a significant impact on the duration of oral mucositis. CLINICAL RELEVANCE: The current study contributes to our understanding of the importance of oral health status in reducing the occurrence, severity, and duration of OM in hematological cancer patients treated with high-dose chemotherapy.
OBJECTIVES: Oral mucositis (OM) is a frequent complication of cancer treatments. Oral mucositis and periodontal disease have a common inflammatory pattern. The purpose of this study was to evaluate the OM and its association with periodontal status in patients with hematologic malignancies who undergo high-dose chemotherapy. MATERIALS AND METHODS: Fifty-five patients who received high-dose chemotherapy were included in the study. Full-mouth periodontal clinical measurements including plaque index (PI), gingival index (GI), clinical attachment level (CAL), and probing depth (PD) values were recorded before the condition chemotherapy regime. OM monitoring was initiated 1 day after the chemotherapy and maintained for 20 days. RESULTS: Twenty-two of patients (40%) were observed oral mucositis after high-dose chemotherapy. Patients with mucositis had significantly higher GI scores than those who did not have mucositis (p < 0.05). There was a significantly moderate positive correlation between the grade of mucositis and GI scores (p < 0.05). In patients with periodontitis, the incidence of grade 1-2 mucositis was significantly higher than in the healthy group (p < 0.05). In individuals with periodontitis and gingivitis, the healing duration of mucositis was significantly longer than the healthy group (p < 0.05). CONCLUSIONS: The results of this study showed that the severity grades of oral mucositis may increase in patients with gingival inflammation. The results also suggest that periodontal diseases may have a significant impact on the duration of oral mucositis. CLINICAL RELEVANCE: The current study contributes to our understanding of the importance of oral health status in reducing the occurrence, severity, and duration of OM in hematological cancer patients treated with high-dose chemotherapy.
Authors: S T Sonis; G Oster; H Fuchs; L Bellm; W Z Bradford; J Edelsberg; V Hayden; J Eilers; J B Epstein; F G LeVeque; C Miller; D E Peterson; M M Schubert; F K Spijkervet; M Horowitz Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: A P Rapoport; L F Miller Watelet; T Linder; S Eberly; R F Raubertas; J Lipp; R Duerst; C N Abboud; L Constine; J Andrews; M A Etter; L Spear; E Powley; C H Packman; J M Rowe; U Schwertschlag; C Bedrosian; J L Liesveld Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544